A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

September 4, 2026 updated by: Eli Lilly and Company

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 317-615-4559
  • Email: LillyTrials@Lilly.com

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1056ABI
        • Recruiting
        • Centro de Investigaciones Metabolicas (CINME)
        • Principal Investigator:
          • Federico Perez Manghi
        • Contact:
          • Phone Number: 08003450697
      • Buenos Aires, Argentina, C1440AAD
        • Recruiting
        • CENUDIAB
        • Contact:
          • Phone Number: 5491128597742
        • Principal Investigator:
          • Alejandra Oviedo
      • CABA, Argentina, C1060ABN
        • Recruiting
        • CEDIC
        • Principal Investigator:
          • Elizabeth Gelersztein
        • Contact:
          • Phone Number: 5491121707326
      • Córdoba, Argentina, 5000
        • Recruiting
        • Instituto de Investigaciones Clínicas Córdoba
        • Contact:
          • Phone Number: 543514253456
        • Principal Investigator:
          • Ines Bartolacci
      • Córdoba, Argentina, X50004FHP
        • Recruiting
        • Clínica Universitaria Reina Fabiola
        • Contact:
          • Phone Number: 35196098294
        • Principal Investigator:
          • Silvina Dominguez Matheu
      • San Nicolás, Argentina, 2900
        • Recruiting
        • Go Centro Medico San Nicolas
        • Contact:
          • Phone Number: 5493364571637
        • Principal Investigator:
          • Paulina Lanchiotti
  • Australia
      • Botany, Australia, 2019
        • Recruiting
        • Emeritus Research
        • Principal Investigator:
          • Paul Bird
      • Brisbane, Australia, 4064
        • Recruiting
        • Core Research Group
        • Contact:
          • Phone Number: 61738765688
        • Principal Investigator:
          • David Colquhoun
      • Camberwell, Australia, 3124
        • Recruiting
        • Emeritus Research
        • Principal Investigator:
          • Sam Francis
      • Coorparoo, Australia, 4151
        • Recruiting
        • Cornerstone Dermatology
        • Principal Investigator:
          • Young Jin Kim
        • Contact:
          • Phone Number: 07 3397 3200
      • Darlinghurst, Sydney, Australia, 2010
        • Recruiting
        • Momentum Darlinghurst
        • Principal Investigator:
          • Mark Bloch
        • Contact:
          • Phone Number: 61 2 9331 7228
      • Maroochydore, Australia, 4558
        • Recruiting
        • CDH Research Institute Pty Ltd
        • Principal Investigator:
          • Hansjoerg Seltenreich
        • Contact:
          • Phone Number: 07 5408 0900
      • Melbourne, Australia, 3021
        • Recruiting
        • Momentum Sunshine
        • Contact:
          • Phone Number: 0395096166
        • Principal Investigator:
          • King Cheung
      • Merewether, Australia, 2291
        • Completed
        • AIM Research
  • Puerto Rico
      • Caguas, Puerto Rico, 00726
        • Recruiting
        • San Juan Bautista School of Medicine - Clinical Research Unit
        • Principal Investigator:
          • Loida Gonzalez-Rodriguez
        • Contact:
          • Phone Number: 787-754-0101 ext. 5054
      • San Juan, Puerto Rico, 00921
        • Recruiting
        • Mgcendo Llc
        • Contact:
          • Phone Number: 7874842757
        • Principal Investigator:
          • Martha Gomez-Cuellar
  • United States
    • Arizona
      • Gilbert, Arizona, United States, 85296
        • Recruiting
        • Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
        • Contact:
          • Phone Number: 480-691-2213
        • Principal Investigator:
          • Sunildat Maheshwari
      • Phoenix, Arizona, United States, 85020
        • Recruiting
        • Synexus Clinical Research US, Inc.
        • Principal Investigator:
          • Shawn Searle
      • Tucson, Arizona, United States, 85741
        • Recruiting
        • Pima Heart
        • Contact:
          • Phone Number: 520329-4139
        • Principal Investigator:
          • Paul Bejarano
    • Florida
      • Sunrise, Florida, United States, 33351
        • Recruiting
        • Precision Clinical Research
        • Principal Investigator:
          • Jeffrey Schneider
    • Georgia
      • Atlanta, Georgia, United States, 30331
        • Recruiting
        • SKY Clinical Research Network Group-Brown
        • Contact:
          • Phone Number: 888-659-4363
        • Principal Investigator:
          • Tamara Brown
      • Lawrenceville, Georgia, United States, 30043
        • Recruiting
        • Teak Research Consults
        • Principal Investigator:
          • Kamar Alabi
      • Sandy Springs, Georgia, United States, 30328
        • Recruiting
        • Agile Clinical Research Trials, LLC
        • Principal Investigator:
          • Vasundhara Cheekati
      • Stonecrest, Georgia, United States, 30038
        • Recruiting
        • Pivotal Research Solutions
        • Contact:
          • Phone Number: 678-825-2887
        • Principal Investigator:
          • LaTrenda Perkins
      • Union City, Georgia, United States, 30291
        • Recruiting
        • Rophe Adult and Pediatric Medicine/SKYCRNG
        • Principal Investigator:
          • Dwight Blake
        • Contact:
          • Phone Number: 470-317-3604
    • Nevada
      • Las Vegas, Nevada, United States, 89128
        • Recruiting
        • Vector Clinical Trials
        • Principal Investigator:
          • Cornell Calinescu
        • Contact:
          • Phone Number: 702-750-0000
    • New Jersey
      • Trenton, New Jersey, United States, 08611
        • Recruiting
        • Premier Research
        • Contact:
          • Phone Number: 609-392-6666
        • Principal Investigator:
          • Herbert Conaway
    • Ohio
      • Dayton, Ohio, United States, 45429
        • Recruiting
        • PriMed Clinical Research
        • Contact:
          • Phone Number: 937-534-4201
        • Principal Investigator:
          • William Randall
    • Texas
      • Dallas, Texas, United States, 75230
        • Recruiting
        • Velocity Clinical Research, Dallas
        • Principal Investigator:
          • Dan Lender
      • Dallas, Texas, United States, 75208
        • Recruiting
        • Mercy Family Clinic
        • Contact:
          • Phone Number: 281-944-3610
        • Principal Investigator:
          • Ebere Israel Azubuike, MD
      • Houston, Texas, United States, 77043
        • Recruiting
        • Biopharma Informatic, LLC
        • Contact:
          • Phone Number: 281-944-3610
        • Principal Investigator:
          • Agadadash Kuliev
      • Houston, Texas, United States, 77079
        • Recruiting
        • PlanIt Research, PLLC
        • Contact:
          • Phone Number: 713-973-3415
        • Principal Investigator:
          • Prashant Koshy
      • Houston, Texas, United States, 77089
        • Recruiting
        • Research Physicians Network, LLC
        • Principal Investigator:
          • Jawad Sarwar, MD
        • Contact:
          • Phone Number: 281-944-3610
      • Richmond, Texas, United States, 77407
        • Recruiting
        • Aavon Clinical Trials
        • Contact:
          • Phone Number: 713-282-5600
        • Principal Investigator:
          • Namrata Dass
      • Shavano Park, Texas, United States, 78231
        • Recruiting
        • Consano Clinical Research, LLC
        • Contact:
          • Phone Number: 210-545-4900
        • Principal Investigator:
          • Michelle Welch
      • Weslaco, Texas, United States, 78596
        • Recruiting
        • Texas Valley Clinical Research
        • Principal Investigator:
          • Eduardo Luna
        • Contact:
          • Phone Number: 956-431-8090
    • Utah
      • West Valley City, Utah, United States, 84120
        • Recruiting
        • Kalo Clinical Research
        • Contact:
          • Phone Number: 801-363-7353
        • Principal Investigator:
          • Cuper Martinez
    • Virginia
      • Norfolk, Virginia, United States, 23510
        • Recruiting
        • Eastern Virginia Medical School (EVMS) Medical Group
        • Principal Investigator:
          • Elias Siraj
        • Contact:
          • Phone Number: 757-446-5291
      • Richmond, Virginia, United States, 23226
        • Recruiting
        • Clinical Research Partners, LLC
        • Contact:
          • Phone Number: 804-477-3045
        • Principal Investigator:
          • Robert Call
    • Washington
      • Bellevue, Washington, United States, 98007
        • Recruiting
        • Northwest Clinical Research Center
        • Principal Investigator:
          • Jeena Vaid
      • Renton, Washington, United States, 98057
        • Recruiting
        • Rainier Clinical Research Center
        • Principal Investigator:
          • Frances Broyles
        • Contact:
          • Phone Number: 425-251-1720
      • Tacoma, Washington, United States, 98405
        • Recruiting
        • Universal Research Group
        • Principal Investigator:
          • Sabrina Benjamin
        • Contact:
          • Phone Number: 253-882-1070

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Have type 2 diabetes
  • Have an HbA1c ≥7.5% to ≤10.5% at screening

  • Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening

    • Diet and exercise
    • Stable dose of metformin
    • Sodium-glucose cotransporter-2 (SGLT2) inhibitor
  • Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening
  • Have a BMI of 27 or greater at screening

Exclusion Criteria:

  • Have any form of diabetes other than type 2 diabetes
  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening

  • Have any of the following cardiovascular conditions within 3 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure

  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include

    • basal or squamous cell skin cancer
    • in situ carcinomas of the cervix, or
    • in situ prostate cancer

  • Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:

    • amylin RA
    • dual amylin and calcitonin RA
    • glucagon-like peptide-1 receptor (GLP-1) RA
    • glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
    • GLP-1/glucagon (GCG) RAs, or
    • GIP/GLP-1/GCG RAs
  • Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
  • Have used insulin for diabetic control within the prior year (short term use in certain situations allowed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Macupatide (Macupatide + Eloralintide Placebo)
Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Drug: Eloralintide Placebo
Administered SC
Experimental: Eloralintide (Elorlintide + Macupatide Placebo)
Participants will be administered eloralintide SC and macupatide placebo SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide Placebo
Administered SC
Experimental: Macupatide + Eloralintide
Participants will be administered eloralintide SC and macupatide SC
Drug: Eloralintide
Administered SC
Other Names:
  • LY3841136
Drug: Macupatide
Administered SC
Other Names:
  • LY3532226
Placebo Comparator: Placebo (Macupatide Placebo + Elorlintide Placebo)
Participants will be administered eloralintide placebo SC and macupatide placebo SC
Drug: Eloralintide Placebo
Administered SC
Drug: Macupatide Placebo
Administered SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percent Change from Baseline in Body Weight
Time Frame: Baseline, Week 32
Baseline, Week 32

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from Baseline in Hemoglobin A1c (HbA1c)
Time Frame: Baseline, Week 32
Baseline, Week 32
Change from Baseline in Body Mass Index (BMI)
Time Frame: Baseline, Week 32
Baseline, Week 32
Change from Baseline in Fasting Glucose
Time Frame: Baseline, Week 32
Baseline, Week 32

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eli Lilly and Company

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 16, 2025

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

October 9, 2025

First Submitted That Met QC Criteria

October 9, 2025

First Posted (Actual)

October 10, 2025

Study Record Updates

Last Update Posted (Actual)

September 8, 2026

Last Update Submitted That Met QC Criteria

September 4, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 27721
  • J2V-MC-GZLF (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe